HomeCompareJNJ vs NDAQ

JNJ vs NDAQ: Dividend Comparison 2026

JNJ yields 2.14% · NDAQ yields 1.29%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NDAQ wins by $110.9K in total portfolio value
10 years
JNJ
Johnson & Johnson
● Live price
2.14%
Share price
$242.49
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.5K
Annual income
$4,749.88
Full JNJ calculator →
NDAQ
NDAQ
● Live price
1.29%
Share price
$83.52
Annual div
$1.08
5Y div CAGR
62.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$141.3K
Annual income
$64,247.81
Full NDAQ calculator →

Portfolio growth — JNJ vs NDAQ

📍 NDAQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodJNJNDAQ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, JNJ + NDAQ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
JNJ pays
NDAQ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

JNJ
Annual income on $10K today (after 15% tax)
$182.28/yr
After 10yr DRIP, annual income (after tax)
$4,037.40/yr
NDAQ
Annual income on $10K today (after 15% tax)
$109.91/yr
After 10yr DRIP, annual income (after tax)
$54,610.64/yr
At 15% tax rate, NDAQ beats the other by $50,573.24/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of JNJ + NDAQ for your $10,000?

JNJ: 50%NDAQ: 50%
100% NDAQ50/50100% JNJ
Portfolio after 10yr
$85.9K
Annual income
$34,498.84/yr
Blended yield
40.17%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on NDAQ right now

JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-5.7% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
NDAQ
Analyst Ratings
23
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$113.60
+36.0% upside vs current
Range: $108.00 — $120.00
Altman Z
2.5
Piotroski
9/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

JNJ buys
8
NDAQ buys
10
PoliticianChamberTickerTypeAmountDate
April Delaney🏢 House$NDAQ▲ Buy$1,001 - $15,0002026-02-27
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricJNJNDAQ
Forward yield2.14%1.29%
Annual dividend / share$5.20$1.08
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR28%62.3%
Portfolio after 10y$30.5K$141.3K
Annual income after 10y$4,749.88$64,247.81
Total dividends collected$15.6K$114.0K
Payment frequencyquarterlyquarterly
SectorHealthcareFinancials
Analyst consensusBuyBuy
Analyst price target$228.73$113.60

Year-by-year: JNJ vs NDAQ ($10,000, DRIP)

YearJNJ PortfolioJNJ Income/yrNDAQ PortfolioNDAQ Income/yrGap
1← crossover$10,594$274.49$10,910$209.87$316.00NDAQ
2$11,294$360.69$12,021$347.30$727.00NDAQ
3$12,133$476.91$13,443$580.44$1.3KNDAQ
4$13,156$635.42$15,368$984.57$2.2KNDAQ
5$14,432$854.61$18,151$1,707.33$3.7KNDAQ
6$16,056$1,162.76$22,481$3,058.70$6.4KNDAQ
7$18,175$1,604.53$29,800$5,746.07$11.6KNDAQ
8$21,009$2,252.68$43,440$11,553.61$22.4KNDAQ
9$24,911$3,229.73$72,027$25,545.86$47.1KNDAQ
10$30,458$4,749.88$141,316$64,247.81$110.9KNDAQ

JNJ vs NDAQ: Complete Analysis 2026

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →

NDAQFinancials

Nasdaq, Inc. operates as a technology company that serves capital markets and other industries worldwide. The Market Technology segment includes anti financial crime technology business, which offers Nasdaq Trade Surveillance, a SaaS solution for brokers and other market participants to assist them in complying with market rules, regulations, and internal market surveillance policies; Nasdaq Automated Investigator, a cloud-deployed anti-money laundering tool; and Verafin, a SaaS technology provider of anti-financial crime management solutions. This segment also handles assets, such as cash equities, equity derivatives, currencies, interest-bearing securities, commodities, energy products, and digital currencies. The Investment Intelligence segment sells and distributes historical and real-time market data; develops and licenses Nasdaq-branded indexes and financial products; and provides investment insights and workflow solutions. The Corporate Platforms segment operates listing platforms; and offers investor relations intelligence and governance solutions. As of December 31, 2021, it had 4,178 companies listed securities on The Nasdaq Stock Market, including 1,632 listings on The Nasdaq Global Select Market; 1,169 on The Nasdaq Global Market; and 1,377 on The Nasdaq Capital Market. The Market Services segment includes equity derivative trading and clearing, cash equity trading, fixed income and commodities trading and clearing, and trade management service businesses. This segment operates various exchanges and other marketplace facilities across various asset classes, which include derivatives, commodities, cash equity, debt, structured products, and exchange traded products; and provides broker, clearing, settlement, and central depository services. The company was formerly known as The NASDAQ OMX Group, Inc. and changed its name to Nasdaq, Inc. in September 2015. Nasdaq, Inc. was founded in 1971 and is headquartered in New York, New York.

Full NDAQ Calculator →
📬

Get this JNJ vs NDAQ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

JNJ vs ABBVJNJ vs MRKJNJ vs PFEJNJ vs BMYJNJ vs LLYJNJ vs SCHDJNJ vs JEPIJNJ vs O

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.